PRME Stock Analysis: Buy, Sell, or Hold?
PRME - Prime Medicine, Inc. Common Stock
$2.93
-0.20 (-6.39%)
▼
5d:
-8.72%
30d:
-20.16%
90d:
-11.21%
HOLD
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Smart Money Accumulation
PRME is down 8.7% this week, but smart money is accumulating calls. Top strike: $4 2026-07-17 with 528 OI. Call ratio: 81% View Scanner →
Strength: 7.5/10
Get Alerted When PRME Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called PRME this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PRME shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: PRME shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: PRME is currently trading at $2.93, which is considered oversold relative to its 30-day fair value range of $3.26 to $3.76.
Technical Outlook: Technically, PRME is in a strong uptrend. The price is currently testing key support at $2.97. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.4% recently.
Market Sentiment: PRME has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.92 (+136.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PRME is in a strong uptrend. The price is currently testing key support at $2.97. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.4% recently.
Market Sentiment: PRME has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.92 (+136.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.26 -
$3.76
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
Protect Your Profits
Holding PRME? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.4%)
- BULLISH: Trading 136.1% below Wall St target ($6.92)
- CAUTION: 5-day price weakness (-8.7%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$3.26 -
$3.76
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.97
Resistance Level
$3.60
Current Trend
Strong Uptrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.37
Wall Street Target
$6.92
(+136.1%)
Revenue Growth (YoY)
-41.1%
Share & Embed Analysis
Last updated: May 18, 2026 9:03 AM ET
Data refreshes hourly during market hours. Next update: 10:02 AM
Data refreshes hourly during market hours. Next update: 10:02 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRME showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$90 | 60 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 62 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 58 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 59 HOLD |
Advanced PRME Option Strategies
Professional options setups generated by AI based on today's PRME price and gamma walls.
